Merck Sharp + Dohme Corp.

Bristol-myers Squibb Compnay

Ian Mangion

Ingyu Jeon

Benjamin D Sherry

Yanfeng Zhang

Jingwu Duan

Nobuyoshi Yasuda

Percy H Carter

Helen Y Chen

Hongmei Li

Peter Emmanuel Maligres

Timothy A Blizzard

Artis Klapars

Fred J Fleitz

Andrew J Tebben

Sookhee Nicole Ha

Ilia A Zavialov

Timothy Allen Blizzard

Gang Qian

Hoa N Nguyen

Nelo R Rivera

Jason Eugene Imbriglio

Jingjun Yin

Yonggang Chen

Donald R Gauthier

Jeffrey Donald Hermes

Jane Yang Wu

Alfred Lee

Yang Cao

Tetsuji Itoh

Candido Gude

Michael Shevlin

Cheng-yi Chen

Seongkon Kim

Michael J McNevin

Rebecca T Ruck

Kung-I Feng

Joyce Stellabott

Yong Liu

Ryan Cohen

Scott Schultz

Christopher J Mortko

Gary Martin

The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.

Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof

The present invention is directed to a process for preparing Tetracyclic Heterocycle Compounds of formula (I): which are useful as HCV NS5A inhibitors. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I). 

Process for preparing tetracyclic heterocycle compounds

The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase, HIV replication and the treatment of human immunodeficiency virus infection in humans.

Process for making reverse transcriptase inhibitors

The present invention is directed to processes for preparing an intermediate for a diazepane compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.

Process for the preparation of an intermediate for an orexin receptor antagonist

The present application describes modulators of MCP-1 or CCR-2 of formula 

Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity

Substituted bicyclic beta-lactams of Formula I: (I), are &#x3b2;-lactamase inhibitors, wherein a, X, Rand Rare defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with &#x3b2;-lactam antibiotics. In particular, the compounds can be employed with a &#x3b2;-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to &#x3b2;-lactam antibiotics due to the presence of the &#x3b2;-lactamases.

&#x3b2;-lactamase inhibitors

Growing community of inventors

Cranford, NJ, United States of America

Ian Mangion